Ambion raises $10.5 million for RNA applications:
This article was originally published in Clinica
Ambion has raised $10.5m in equity financing from investors led by Telegraph Hill Partners of San Francisco, California. Austin, Texas-based Ambion develops RNA-based products for molecular diagnostics and life science research. Its ribonuclease-resistant RNA assays and SNP detection technology is already licensed by diagnostics companies in the fields of HIV and hepatitis C detection, and in urine screening for bladder cancer.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.